Insights
Report Library
Browse our full archive of reports. Filter by health area, disease or condition, product, and date. Written by our expert analysts, our reports highlight key messages in the data, make the case for change and offer actionable recommendations.
10 min read
AS01 adjuvant in M72 vaccine: from malaria research to tackling tuberculosis
The AS01 adjuvant, initially advanced through GSK and PATH’s RTS,S malaria vaccine global health research programme, before being adopted across a range of diseases and vaccines candidates, including to enhance the effectiveness of the M72/AS01E candidate vaccine for tuberculosis (TB).
10 min read
Rotarix: preventing diarrhoeal disease across the globe
The Rotarix rotavirus vaccine was developed by GSK following the side effects-driven withdrawal of the earlier RotaShield vaccine. GSK deliberately adopted a ‘South-first’ access strategy for Rotarix, using trials and distribution in Latin America to build the evidence base that led to its widespread adoption throughout the rich world.
10 min read
From a multi-dose schedule to a single dose: how LMIC research can unlock the full potential of HPV vaccination
The human papillomavirus (HPV) vaccine moved from a two-dose schedule to a single dose for eligible individuals in the primary target group- girls aged 9-14 years. This change was based on innovative research from LMICs that is now being adopted in the UK and has huge potential for scale up across LMICs and HICs alike.
10 min read
DFMO: from sleeping sickness to treating children’s cancer
DFMO was briefly conceived as a cancer treatment, but, after failing initial trials, it was successfully developed as a treatment for sleeping sickness in Africa, before being repurposed as a cream for unwanted facial hair and finally coming full circle as an FDA-approved treatment for paediatric neuroblastoma.
10 min read
AS01 adjuvant in Arexvy: from malaria research to protecting ageing populations
The AS01 adjuvant was initially advanced through the RTS,S malaria vaccine research programme, before being adopted to enhance the effectiveness of GSK’s ‘Arexvy’ respiratory syncytial virus (RSV) vaccine in older people.
10 min read
The Ripple Effect 3.0: deepening the case for the domestic benefits of global health
Five new case studies, providing quantitative, country-specific proof points showing how these selected global health innovations improve health outcomes and deliver health system cost savings in the UK, US, Japan and Europe.
-404x270.webp)
10 min read
From commitment to capability: Are current R&D trends delivering on Africa’s health sovereignty ambitions?
The first publication in the R&D Blindspots Policy Series examines a pressing question for the continent: is research and development truly delivering Africa’s vision for health security and sovereignty?
Impact Global Health and PATH29 Apr 2026
15 min read
Funding for global health R&D in 2024
An overview of key takeaways from the G-FINDER survey
-404x404.webp)
15 min read
100 Days Mission: 5th Implementation Report and Scorecard
The 100 Days Mission's 5th Implementation Report and Scorecard highlight limited progress has been made in an R&D ecosystem that remains reactive and reliant on US funding.
You may also be interested in
Hubs
Your destination for a curated collection of data, insights and tools on the most pressing global health topics. Explore our hubs on Women’s Health, the Impact of Global Health R&D, and more to launch in the future.
Health Areas
Our Health Areas resource gives you an at-a-glance summary of the state of innovation and annual R&D investment by disease and condition. Updated regularly, this is a unique quick reference for the global health community.